NDAORALCAPSULE, EXTENDED RELEASE
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
5/8 — Partial
DETROL LA (tolterodine tartrate) by Viatris is receptors. First approved in 2000.
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DETROL LA is an extended-release oral capsule containing tolterodine tartrate, a selective muscarinic receptor antagonist approved in 2000. It treats overactive bladder by reducing urinary frequency and urgency through blockade of cholinergic muscarinic receptors in the bladder. The drug is metabolized to 5-hydroxymethyl tolterodine (5-HMT), an active metabolite that contributes significantly to therapeutic effect.
$0.001BPart D
LOE ApproachingDeclining
Product is in late-stage patent life with minimal Part D volume (1,762 claims in 2023), indicating a mature, declining franchise with reduced commercial team expansion opportunities.
Mechanism of Action
receptors. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of 5-hydroxymethyl tolterodine (5-HMT), the major pharmacologically active metabolite. 5-HMT,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
Started Mar 2010
322 enrolled
Overactive Bladder
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
Started Sep 2008
20 enrolled
Overactive Bladder
Effects Of Detrol LA On Memory And Cognition In Elderly Population
Started Dec 2006
220 enrolled
MemoryCognition
Detrol LA In Men With Overactive Bladder.
Started Jan 2006
600 enrolled
Overactive Bladder (OAB)
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
Started Oct 2005
417 enrolled
Urinary Incontinence
Worked on DETROL LA at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.